Latest Ratios: P/E Ratio 0.8x · EV/EBITDA N/A · ROE 27.1%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $5M | $399M | $209.2B | — | — | — |
| Enterprise Value | $-1642266 | $392M | $209.2B | — | — | — |
| P/E Ratio → | 0.84 | 126.06 | 16120.75 | — | — | — |
| P/S Ratio | 0.15 | 12.16 | 4310.75 | — | — | — |
| P/B Ratio | 0.15 | 22.95 | 18555.54 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.96 | 4310.64 | — | — | — |
| EV / EBITDA | — | — | 121049.80 | — | — | — |
| EV / EBIT | — | 93.54 | 117736.74 | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 2.8% | 2.8% | 5.7% | 7.3% | 4.0% | 4.7% |
| Operating Margin | -6.1% | -6.1% | 3.5% | 4.2% | 1.7% | 2.6% |
| Net Profit Margin | 11.8% | 11.8% | 2.7% | 3.4% | 1.5% | 2.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 27.1% | 27.1% | 20.1% | 1923.7% | — | — |
| ROA | 20.9% | 20.9% | 12.9% | 38.7% | 14.6% | 10.8% |
| ROIC | -18.1% | -18.1% | 36.6% | 73.9% | — | — |
| ROCE | -13.6% | -13.6% | 25.4% | 566.7% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.11 | 0.54 | — | — |
| Debt / EBITDA | — | — | 0.70 | 0.71 | 1.87 | 1.01 |
| Net Debt / Equity | — | -0.38 | -0.48 | -0.23 | — | — |
| Net Debt / EBITDA | — | — | -3.16 | -0.29 | 0.78 | 3.29 |
| Debt / FCF | — | — | — | — | — | 0.41 |
| Interest Coverage | 91.25 | 91.25 | 43.13 | 57.95 | 27.06 | 62.72 |
Net cash position: cash ($9M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.05 | 5.05 | 3.98 | 1.43 | 0.22 | 0.56 |
| Quick Ratio | 5.05 | 5.05 | 2.64 | 0.49 | 0.22 | 0.46 |
| Cash Ratio | 2.22 | 2.22 | 1.72 | 0.47 | 0.15 | 0.01 |
| Asset Turnover | — | 1.52 | 3.13 | 6.32 | 29.76 | 4.57 |
| Inventory Turnover | — | — | 8.85 | 10.88 | — | 25.97 |
| Days Sales Outstanding | — | 58.82 | 26.70 | 0.86 | 0.09 | 56.01 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 0.8% | 0.0% | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $12M | $11M | $10M | $10M |
Regulatory and margin compression
As reported in recent financial filings, HAO trades at a P/S ratio of 0.14, a valuation level that suggests the market is pricing the firm as a distressed service provider rather than a growth-oriented technology platform, given the significant -32.39% year-over-year revenue contraction observed.
The extremely low P/S multiple indicates that investors are heavily discounting the company's future revenue potential due to the lack of a defensible moat. This valuation appears to imply that the market expects further top-line erosion, as the current price fails to account for any meaningful recovery in the healthcare advertising vertical.
Based on the company's reported figures, ROIC has plummeted to -39.6% in 2026Q2, marking a sharp reversal from the positive returns seen in 2024 and highlighting the company's inability to generate value from its invested capital in the current competitive environment.
The rapid decay in ROIC suggests that the company's core business model is failing to cover its cost of capital, likely due to the combination of razor-thin gross margins and rising operating expenses. Investors should monitor whether management can stabilize these returns, as the current trajectory indicates a destruction of shareholder value.
According to the provided financial data, the company's asset turnover has fluctuated significantly, dropping to 1.60 in 2026Q2 from a peak of 7.27 in 2022, which suggests a declining ability to generate revenue from the firm's existing asset base in a highly competitive market.
The volatility in asset turnover reflects the transactional nature of the business and the difficulty in maintaining consistent ad-spend volume. This inefficiency, combined with the lack of proprietary technology, suggests that the company is struggling to optimize its working capital cycle effectively against larger, more integrated competitors.
As indicated by the balance sheet, HAO maintains a current ratio of 3.45 as of 2026Q2, yet this liquidity position appears somewhat superficial given the persistent negative operating cash flow and the company's reliance on cash reserves to fund ongoing operational deficits.
While the current ratio suggests a comfortable cushion, the lack of cash generation from core operations means that this liquidity is essentially a finite resource. If the company cannot pivot to a self-sustaining model, the current liquidity buffer may be rapidly depleted by ongoing operating losses.
Based on reported figures, the 11.82% net margin is a commonly misapplied metric for HAO, as it obscures the underlying -6.10% operating margin and fails to account for the fact that bottom-line profitability is driven by non-operating items rather than core advertising services.
Analysts should prioritize gross profit or net revenue as the true measure of economic activity, as the net margin is heavily distorted by non-recurring gains or interest income. Relying on net income as a proxy for operational health may lead to a significant overestimation of the company's long-term viability.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HAO stock.
Haoxi Health Technology Limited's current P/E ratio is 0.8x. The historical average is 126.1x.
Haoxi Health Technology Limited's return on equity (ROE) is 27.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 23.6%.
Based on historical data, Haoxi Health Technology Limited is trading at a P/E of 0.8x. Compare with industry peers and growth rates for a complete picture.
Haoxi Health Technology Limited has 2.8% gross margin and -6.1% operating margin.